Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics

被引:6
|
作者
Ngo, Lien [1 ]
Yoo, Hee-Doo [1 ]
Tran, Phuong [1 ]
Cho, Hea-Young [2 ]
Lee, Yong-Bok [1 ]
机构
[1] Chonnam Natl Univ, Inst Bioequivalence & Bridging Study, Coll Pharm, 77 Yongbong Ro, Gwangju 61186, South Korea
[2] CHA Univ, Coll Pharm, 335 Pangyo Ro, Seongnam Si 13488, Gyeonggido, South Korea
基金
新加坡国家研究基金会;
关键词
Rebamipide; Population; Pharmacokinetics; Genetic polymorphism; MDR1; MULTIDRUG-RESISTANCE GENE; P-GLYCOPROTEIN EXPRESSION; ORAL BIOAVAILABILITY; HELICOBACTER-PYLORI; ANTIULCER AGENT; SOLID DISPERSION; MALE-VOLUNTEERS; MDR1; GENE; POLYMORPHISMS; DRUG;
D O I
10.1007/s10928-017-9519-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this study, the population pharmacokinetic (PK) analysis of rebamipide (Reba) in healthy male Korean subjects was analyzed using the nonlinear mixed effects modeling method. The possible effects of physiological covariates and the multidrug resistance (MDR1) gene 3435C > T polymorphism on PK parameters were also investigated. Data were collected from a bioequivalence study, in which 26 subjects who participated in the study were administered a single oral dose of 100 mg Reba; only data from the reference formulation were used. Reba showed a relatively large inter-individual variability (from 2.6- to 3.3-fold) in the PK parameters with double peaks or the concentration plateau after the peak concentration in its serum concentration-time profiles. The population PKs of Reba was best described by a one-compartment model with three fraction absorption processes followed a single Weibull-type function and two first-order kinetics, and lag times. The study suggests that the efflux transporter MDR1 3435C > T allele affects the substantial inter-individual variability in the absorption of Reba according to genetic polymorphism. A significant difference was found in the absorption rate ka (1) among the MDR1 3435C > T genotype groups (P < 0.05) (CT group, 79.8% increase; and TT group, 115% increase). The use of combined MDR1 3435C > T and body mass index as covariates for ka (1) exerted a more significant effect (P < 0.05). In addition, body surface area significantly affected the apparent total clearance (P < 0.05).
引用
下载
收藏
页码:291 / 303
页数:13
相关论文
共 50 条
  • [1] Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics
    Lien Ngo
    Hee-Doo Yoo
    Phuong Tran
    Hea-Young Cho
    Yong-Bok Lee
    Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44 : 291 - 303
  • [2] Population Pharmacokinetic Analysis of Simvastatin and its Active Metabolite with the Characterization of Atypical Complex Absorption Kinetics
    Jin, Seok-Joon
    Bae, Kyun-Seop
    Cho, Sang-Heon
    Jung, Jin-Ah
    Kim, Unjib
    Choe, Sangmin
    Ghim, Jong-Lyul
    Noh, Yook-Hwan
    Park, Hyun-Jung
    Kim, Hee-sun
    Lim, Hyeong-Seok
    PHARMACEUTICAL RESEARCH, 2014, 31 (07) : 1801 - 1812
  • [3] Population Pharmacokinetic Analysis of Simvastatin and its Active Metabolite with the Characterization of Atypical Complex Absorption Kinetics
    Seok-Joon Jin
    Kyun-Seop Bae
    Sang-Heon Cho
    Jin-Ah Jung
    Unjib Kim
    Sangmin Choe
    Jong-Lyul Ghim
    Yook-Hwan Noh
    Hyun-Jung Park
    Hee-sun Kim
    Hyeong-Seok Lim
    Pharmaceutical Research, 2014, 31 : 1801 - 1812
  • [4] Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects
    Jeong, Seung-Hyun
    Jang, Ji-Hun
    Cho, Hea-Young
    Lee, Yong-Bok
    PHARMACEUTICS, 2021, 13 (05)
  • [5] Population Pharmacokinetic Analysis of Tiropramide in Healthy Korean Subjects
    Jeong, Seung-Hyun
    Jang, Ji-Hun
    Cho, Hea-Young
    Lee, Yong-Bok
    PHARMACEUTICS, 2020, 12 (04)
  • [6] A population Pharmacokinetic Analysis of Telaprevir in Healthy Korean and Japanese Subjects
    Choi, Yewon
    Yoon, Seonghae
    Lee, SeungHwan
    Yu, Kyung-Sang
    Jang, In-Jin
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S83 - S83
  • [7] POPULATION PHARMACOKINETIC ANALYSIS OF LENALIDOMIDE IN HEALTHY KOREAN SUBJECTS.
    Park, J. -S.
    Jeon, J. -Y.
    Jang, K.
    Moon, S.
    Kim, M. -G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S67 - S67
  • [8] POPULATION PHARMACOKINETIC ANALYSIS OF SUMATRIPTAN IN HEALTHY KOREAN MALE SUBJECTS.
    Lee, J.
    Seong, S.
    Park, S.
    Gwon, M.
    Jang, Y.
    Lee, H.
    Yoo, H.
    Yoon, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S76 - S77
  • [9] Population Pharmacokinetic Analysis of Lanreotide Autogel® in Healthy Subjects
    Troconiz, Inaki F.
    Cendros, Josep-Maria
    Peraire, Concepcion
    Ramis, Joaquim
    Garrido, Maria J.
    Boscani, Paolo F.
    Obach, Rosendo
    CLINICAL PHARMACOKINETICS, 2009, 48 (01) : 51 - 62
  • [10] Population pharmacokinetic analysis of rimonabant in healthy subjects.
    Ferron, GM
    Grandison, M
    Lockwood, G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P43 - P43